CDK12 and prostate carcinoma: Contrary to initial expectations, prostate cancer cases with CDK12 mutations were found not to have typical HRD features; furthermore, there are several lines of evidences suggesting that CDK12-associated PCs demonstrate comparatively low sensitivity to PARP inhibitors [10,45,46,47].